EP3746451 - BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 17.05.2024 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 09.06.2023 | ||
Former | Grant of patent is intended Status updated on 06.02.2023 | ||
Former | Examination is in progress Status updated on 18.02.2022 | ||
Former | Request for examination was made Status updated on 07.02.2022 | ||
Former | Grant of patent is intended Status updated on 04.11.2021 | ||
Former | Request for examination was made Status updated on 18.10.2021 | ||
Former | Grant of patent is intended Status updated on 04.07.2021 | ||
Former | Request for examination was made Status updated on 06.11.2020 | ||
Former | The international publication has been made Status updated on 10.08.2019 | ||
Former | unknown Status updated on 11.02.2019 | Most recent event Tooltip | 30.08.2024 | Lapse of the patent in a contracting state New state(s): MC | published on 02.10.2024 [2024/40] | Applicant(s) | For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | [2020/50] | Inventor(s) | 01 /
TRIESELMANN, Thomas Boehringer Ingelheim International GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | 02 /
GODBOUT, Cédrickx Boehringer Ingelheim International GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | 03 /
HOENKE, Christoph Boehringer Ingelheim International GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | 04 /
VINTONYAK, Viktor Boehringer Ingelheim International GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | [2020/50] | Representative(s) | Lutze, Oliver, et al Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE | [N/P] |
Former [2020/50] | Simon, Elke Anna Maria, et al Boehringer Ingelheim GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | Application number, filing date | 19702246.0 | 28.01.2019 | [2020/50] | WO2019EP51989 | Priority number, date | EP20180154824 | 02.02.2018 Original published format: EP 18154824 | [2020/50] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019149657 | Date: | 08.08.2019 | Language: | EN | [2019/32] | Type: | A1 Application with search report | No.: | EP3746451 | Date: | 09.12.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.08.2019 takes the place of the publication of the European patent application. | [2020/50] | Type: | B1 Patent specification | No.: | EP3746451 | Date: | 12.07.2023 | Language: | EN | [2023/28] | Search report(s) | International search report - published on: | EP | 08.08.2019 | Classification | IPC: | C07D498/04, C07D519/00, A61P3/00, A61P3/10, A61K31/437, A61K31/444, A61K31/5377, A61K31/497, A61K31/501, A61K31/4545 | [2020/50] | CPC: |
C07D498/04 (EP,IL,KR,US);
A61K31/437 (KR);
A61K31/444 (KR);
A61P3/00 (EP,IL);
A61P3/04 (KR);
A61P3/10 (EP,IL,KR);
C07D519/00 (EP,IL,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/50] | Extension states | BA | 02.09.2020 | ME | 02.09.2020 | Validation states | MA | 02.09.2020 | TN | 02.09.2020 | Title | German: | BENZYL-, (PYRIDIN-3-YL)METHYL- ODER (PYRIDIN-4-YL)METHYL-SUBSTITUIERTE OXADIAZOLOPYRIDINDERIVATE ALS INHIBITOREN DER GHRELIN-O-ACYL-TRANSFERASE (GOAT) | [2020/50] | English: | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | [2020/50] | French: | DÉRIVÉS D'OXADIAZOLOPYRIDINE À SUBSTITUTION BENZYLE, (PYRIDIN-3-YL)MÉTHYLE OU (PYRIDIN-4-YL)MÉTHYLE UTILISÉS EN TANT QU'INHIBITEURS DE LA GHRÉLINE O-ACYLTRANSFÉRASE (GOAT) | [2020/50] | Entry into regional phase | 02.09.2020 | National basic fee paid | 02.09.2020 | Designation fee(s) paid | 02.09.2020 | Examination fee paid | Examination procedure | 14.08.2020 | Amendment by applicant (claims and/or description) | 02.09.2020 | Examination requested [2020/50] | 02.09.2020 | Date on which the examining division has become responsible | 05.07.2021 | Communication of intention to grant the patent | 15.10.2021 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 05.11.2021 | Communication of intention to grant the patent | 07.02.2022 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 17.02.2022 | Despatch of a communication from the examining division (Time limit: M02) | 25.03.2022 | Reply to a communication from the examining division | 07.02.2023 | Communication of intention to grant the patent | 31.05.2023 | Fee for grant paid | 31.05.2023 | Fee for publishing/printing paid | 31.05.2023 | Receipt of the translation of the claim(s) | Opposition(s) | 15.04.2024 | No opposition filed within time limit [2024/25] | Fees paid | Renewal fee | 01.02.2021 | Renewal fee patent year 03 | 31.01.2022 | Renewal fee patent year 04 | 31.01.2023 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AT | 12.07.2023 | CZ | 12.07.2023 | DK | 12.07.2023 | EE | 12.07.2023 | ES | 12.07.2023 | FI | 12.07.2023 | HR | 12.07.2023 | IT | 12.07.2023 | LT | 12.07.2023 | LV | 12.07.2023 | MC | 12.07.2023 | NL | 12.07.2023 | PL | 12.07.2023 | RO | 12.07.2023 | RS | 12.07.2023 | SE | 12.07.2023 | SI | 12.07.2023 | SK | 12.07.2023 | SM | 12.07.2023 | NO | 12.10.2023 | GR | 13.10.2023 | IS | 12.11.2023 | PT | 13.11.2023 | [2024/40] |
Former [2024/36] | AT | 12.07.2023 | |
CZ | 12.07.2023 | ||
DK | 12.07.2023 | ||
EE | 12.07.2023 | ||
ES | 12.07.2023 | ||
FI | 12.07.2023 | ||
HR | 12.07.2023 | ||
IT | 12.07.2023 | ||
LT | 12.07.2023 | ||
LV | 12.07.2023 | ||
NL | 12.07.2023 | ||
PL | 12.07.2023 | ||
RO | 12.07.2023 | ||
RS | 12.07.2023 | ||
SE | 12.07.2023 | ||
SI | 12.07.2023 | ||
SK | 12.07.2023 | ||
SM | 12.07.2023 | ||
NO | 12.10.2023 | ||
GR | 13.10.2023 | ||
IS | 12.11.2023 | ||
PT | 13.11.2023 | ||
Former [2024/26] | AT | 12.07.2023 | |
CZ | 12.07.2023 | ||
DK | 12.07.2023 | ||
EE | 12.07.2023 | ||
ES | 12.07.2023 | ||
FI | 12.07.2023 | ||
HR | 12.07.2023 | ||
IT | 12.07.2023 | ||
LT | 12.07.2023 | ||
LV | 12.07.2023 | ||
NL | 12.07.2023 | ||
PL | 12.07.2023 | ||
RO | 12.07.2023 | ||
RS | 12.07.2023 | ||
SE | 12.07.2023 | ||
SK | 12.07.2023 | ||
SM | 12.07.2023 | ||
NO | 12.10.2023 | ||
GR | 13.10.2023 | ||
IS | 12.11.2023 | ||
PT | 13.11.2023 | ||
Former [2024/23] | AT | 12.07.2023 | |
CZ | 12.07.2023 | ||
DK | 12.07.2023 | ||
EE | 12.07.2023 | ||
ES | 12.07.2023 | ||
FI | 12.07.2023 | ||
HR | 12.07.2023 | ||
LT | 12.07.2023 | ||
LV | 12.07.2023 | ||
NL | 12.07.2023 | ||
PL | 12.07.2023 | ||
RO | 12.07.2023 | ||
RS | 12.07.2023 | ||
SE | 12.07.2023 | ||
SK | 12.07.2023 | ||
SM | 12.07.2023 | ||
NO | 12.10.2023 | ||
GR | 13.10.2023 | ||
IS | 12.11.2023 | ||
PT | 13.11.2023 | ||
Former [2024/22] | AT | 12.07.2023 | |
CZ | 12.07.2023 | ||
DK | 12.07.2023 | ||
ES | 12.07.2023 | ||
FI | 12.07.2023 | ||
HR | 12.07.2023 | ||
LT | 12.07.2023 | ||
LV | 12.07.2023 | ||
NL | 12.07.2023 | ||
PL | 12.07.2023 | ||
RO | 12.07.2023 | ||
RS | 12.07.2023 | ||
SE | 12.07.2023 | ||
SM | 12.07.2023 | ||
NO | 12.10.2023 | ||
GR | 13.10.2023 | ||
IS | 12.11.2023 | ||
PT | 13.11.2023 | ||
Former [2024/20] | AT | 12.07.2023 | |
ES | 12.07.2023 | ||
FI | 12.07.2023 | ||
HR | 12.07.2023 | ||
LT | 12.07.2023 | ||
LV | 12.07.2023 | ||
NL | 12.07.2023 | ||
PL | 12.07.2023 | ||
RS | 12.07.2023 | ||
SE | 12.07.2023 | ||
SM | 12.07.2023 | ||
NO | 12.10.2023 | ||
GR | 13.10.2023 | ||
IS | 12.11.2023 | ||
PT | 13.11.2023 | ||
Former [2024/10] | AT | 12.07.2023 | |
ES | 12.07.2023 | ||
FI | 12.07.2023 | ||
HR | 12.07.2023 | ||
LT | 12.07.2023 | ||
LV | 12.07.2023 | ||
NL | 12.07.2023 | ||
PL | 12.07.2023 | ||
RS | 12.07.2023 | ||
SE | 12.07.2023 | ||
NO | 12.10.2023 | ||
GR | 13.10.2023 | ||
IS | 12.11.2023 | ||
PT | 13.11.2023 | ||
Former [2024/09] | AT | 12.07.2023 | |
ES | 12.07.2023 | ||
FI | 12.07.2023 | ||
LT | 12.07.2023 | ||
NL | 12.07.2023 | ||
SE | 12.07.2023 | ||
NO | 12.10.2023 | ||
GR | 13.10.2023 | ||
IS | 12.11.2023 | ||
Former [2024/08] | LT | 12.07.2023 | |
NL | 12.07.2023 | ||
NO | 12.10.2023 | ||
GR | 13.10.2023 | ||
Former [2024/05] | NL | 12.07.2023 | Cited in | International search | [AD]WO2013125732 (TAKEDA PHARMACEUTICAL [JP]) [AD] 1-14 * the whole document *; | [AD]WO2015073281 (LILLY CO ELI [US]) [AD] 1-14 * the whole document *; | [A]WO2016044467 (UNIV CALIFORNIA [US]) [A] 1-14 * the whole document *; | [A]WO2016168225 (LILLY CO ELI [US]) [A] 1-14 * the whole document *; | [A]WO2016168222 (LILLY CO ELI [US]) [A] 1-14 * the whole document *; | [A] - L S Vasil"ev ET AL, "Reactions of cyanofurazans with [beta]-dicarbonyl compounds", Russian Chemical Bulletin, New York, doi:10.1023/A:1014075327382, (20010701), pages 1280 - 1286, URL: https://link.springer.com/content/pdf/10.1023/A:1014075327382.pdf, XP055562527 [A] 1-14 * compounds 8a, 8b, 8c, 10a, 10b * DOI: http://dx.doi.org/10.1023/A:1014075327382 | by applicant | WO2008101017 | WO2008152403 | WO2010070252 | WO2010070253 | WO2010070255 | WO2010070251 | WO2011006497 | WO2011160630 | WO2011160633 | WO2013092703 | WO2013125732 | WO2014041195 | WO2015073281 | - D.E. CUMMINGS et al., Diabetes, (20010000), vol. 50, no. 8, pages 1714 - 1719 | - M.R. DRUCE et al., Int. J. Obes., (20050000), vol. 29, no. 9, pages 1130 - 1136 | - W. ZHANG et al., Endocrinology, (20080000), vol. 149, no. 9, pages 4710 - 4716 | - N. WIERUP et al., Regulatory Peptides, (20020000), vol. 107, pages 63 - 69 | - R.J. KUPPENS et al., Endocrine, (20150000), vol. 50, no. 3, pages 633 - 642 | - F. BROGLIO et al., J.Clin.Endocrinol.Metab., (20040000), vol. 89, pages 3062 - 3065 | - A. DELPARIGI et al., J. Clin. Endocrinol. Metab., (20020000), vol. 87, no. 12, pages 5461 - 5464 | - R. GRANATA et al., Endocrinology, (20070000), vol. 148, no. 2, pages 512 - 529 | - R. GRANATA et al., J. Med. Chem., (20120000), vol. 55, no. 6, pages 2585 - 2596 | - Chemistry of Heterocyclic Compounds (New York, NY, United States, (19940000), vol. 30, pages 608 - 611 | - T. W. GREENE; P. G. M. WUTS, Protective Groups in Organic Synthesis, Wiley-Interscience | - HAFFNER et al., Diabetes, (20050000), vol. 54, pages 1566 - 1572 |